Heligenics: Funding, Investors & Team (Sep 2026)
Heligenics is a life science company that develops a technology showing the genetic mutation impact to transform genetic testing and drug development for major diseases. It measures the significance of mutations in the human genome through a parallel in-vitro process called the GigaAssay, measuring the impact of all potential amino acid substitutions in the functional target protein, doing in a few months what would take many years to do it at all. For cancer diagnostics companies, Heligenics' functional data enables improved genetic test interpretation, and for pharmaceutical companies, it empowers the conversion of generic drugs into targeted precision medicines or can rescue a failed drug candidate through the identification of variants for a redesigned genetically-stratified clinical trial. The Las Vegas, Nevada-headquartered company was established by Martin Schiller in 2017.
Heligenics has raised $3.4M across 2 funding rounds on record, the most recent an undisclosed round of $2.2M announced in Aug 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Heligenics Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Heligenics Funding Rounds
Heligenics raised $1.2M in an undisclosed round announced in Dec 2020.
1.7 years later, an undisclosed round of $2.2M was announced in Aug 2022.
Heligenics Founders and Leadership Team
Contact details for the Heligenics team: 1 of 1 has an email address on file.
Start 14-day free trial →Heligenics Funding Compared to Other Biotechnology Startups
Heligenics' latest round of $2.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Heligenics in Biotechnology and Las Vegas
Companies Similar to Heligenics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Heligenics Funding FAQs
What does Heligenics do?
Heligenics is a life science company that develops a technology showing the genetic mutation impact to transform genetic testing and drug development for major diseases. It measures the significance of mutations in the human genome through a parallel in-vitro process called the GigaAssay, measuring the impact of all potential amino acid substitutions in the functional target protein, doing in a few months what would take many years to do it at all. For cancer diagnostics companies, Heligenics' functional data enables improved genetic test interpretation, and for pharmaceutical companies, it empowers the conversion of generic drugs into targeted precision medicines or can rescue a failed drug candidate through the identification of variants for a redesigned genetically-stratified clinical trial. The Las Vegas, Nevada-headquartered company was established by Martin Schiller in 2017.
How much funding has Heligenics raised?
Heligenics has raised $3.4M across 2 rounds on record. The most recent is an undisclosed round of $2.2M announced in Aug 2022.
When did Heligenics last raise funding?
Heligenics' most recent funding round on record is an undisclosed round of $2.2M, announced in Aug 2022.
Who is the CEO of Heligenics?
Martin Schiller is listed as CEO at Heligenics.
Where is Heligenics headquartered?
Heligenics is based in Las Vegas, Nevada, United States.
How many employees does Heligenics have?
Heligenics is in the 11-50 employee band.
How does Heligenics' funding compare to other Biotechnology startups?
Heligenics' latest round of $2.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Heligenics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Heligenics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.